How will Medicare drug price negotiations impact employer costs?

Last month, CMS released a list of the first 10 drugs that will be eligible for Medicare price negotiations under the Inflation Reduction Act (IRA). And while these government negotiations may create a “spill-over” effect and allow employers to also negotiate better prices, others worry they may end up increasing costs for commercial health plans as drug manufacturers try to make up their margins, Sara Hansard writes for Bloomberg Law.

Background